| |
March 18-20, 2024 | Savannah, GA The Fierce TMF Summit is the must-attend event for clinical document management professionals to learn, network and connect. Gain invaluable insights from unique case studies, panels, and workshops, and access the best networking the industry has to offer. Register now and SAVE $300 until February 23 to take your TMF to the next level. Sign up today!
|
|
Today’s Big NewsFeb 12, 2024 |
| By Annalee Armstrong,Gabrielle Masson More biotech companies filed for bankruptcy in 2023 than any year since 2010, underscoring a brutal year defined by layoffs, company closures and pipeline reprioritizations. |
|
|
|
By Annalee Armstrong Gilead is bolstering its liver disease portfolio with the $4.3 billion acquisition of CymaBay Therapeutics, specifically for the primary biliary cholangitis med seladelpar. |
By James Waldron CSL’s largest-ever trial has ended in failure, as the Australian pharma revealed that its cholesterol efflux enhancer was unable to reduce the risk of heart attacks. |
Sponsored by Questex Fierce Life Sciences and Healthcare sit down with biotech, pharma, and healthcare executives at Fierce JPM Week. |
By Gabrielle Masson The efficacy of Moderna’s investigational RSV vaccine appears to wane faster than GSK’s approved shot Arexvy, a revelation that sent the Big Biotech’s stock slipping. |
By James Waldron Just five months after launching the phase 3 part of a lung disease trial for its sole clinical asset, AN2 Therapeutics is pressing pause. |
By James Waldron What do you get when you merge six dermatology disease-focused biotechs into one? Medicxi plans to find out. |
By Max Bayer Kyverna's $319 million IPO offers more evidence that biotech's once-icy public markets are thawing. And investors are clearly clamoring for cell therapies aimed at autoimmune diseases. |
By Helen Floersh Athira Pharma’s amyotrophic lateral sclerosis drug ATH-1105 appears to boost survival and reduce motor function decline in mouse models of the disease. The company intends to test ATH-1105 in humans in the first half of 2024. |
By Nick Paul Taylor Pfizer has touched down at the Super Bowl. The Big Pharma ran its “Here’s to Science” ad at the event, framing its work to “outdo cancer” as part of a history of breakthroughs dating back to Hippocrates. |
By Heather Landi,Paige Minemyer,Dave Muoio,Noah Tong,Frank Diamond,Anastassia Gliadkovskaya,Annie Burky,Susan Kreimer Meet the winners of Fierce Healthcare's Fierce 15 of 2024. |
Fierce podcastsDon’t miss an episode |
| | This week on “The Top Line,” we explore the most anticipated drug launches of 2024. Editor-in-Chief Ayla Ellison engages in a conversation with Fierce Pharma Marketing Senior Editor Ben Adams about the drugs likely to launch this year with the most significant sales potential by 2028. |
|
|---|
|
|
|
Wednesday, February 28, 2024 | 11am ET / 8am PT While oral minitablets can offer several advantages in pharmaceutical applications, manufacturing them can be a complex challenge. Join industry experts for a discussion on the intricate journey of drug development, with a look at how minitablets have redefined formulation strategies, efficacy, patient-centric solutions, options for lifecycle management, and more. Sign up now!
|
|
| Whitepaper This paper offers a detailed review of key events and developments in the oncology market during 2023. It’s a helpful “status report” that informs how the market is likely to evolve in 2024. It covers, vaccines, radiopharmaceuticals, ADCs, CAR-Ts, bi-specifics, & more. Presented by Blue Matter, strategic consultants in the life sciences |
| Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
| |
|
